Compare Stocks

Enter up to five stock symbols separated by a comma or space (ex. BAC,WFC,JPM,LON:BARC).
Date Range: 

 ArsanisOptiBiotix HealthHvivo4basebio UK SocietasIXICO
SymbolNASDAQ:ASNSLON:OPTILON:HVOLON:4BBLON:IXI
Price Information
Current Price$3.11GBX 52.50GBX 52.14GBX 343GBX 73.59
52 Week RangeN/AN/AN/AN/ABuy
MarketRank™
Overall Score1.10.40.50.31.0
Analysis Score0.00.00.00.00.0
Community Score2.22.12.70.02.8
Dividend Score0.00.00.00.00.0
Ownership Score2.50.00.01.71.7
Earnings & Valuation Score0.60.00.00.00.6
Analyst Ratings
Consensus RecommendationN/AN/AN/AN/ABuy
Consensus Price TargetN/AN/AN/AN/AN/A
% Upside from Price TargetN/AN/AN/AN/AN/A
Trade Information
Market Cap$45.53 million£47.49 million£43.62 million£41.26 million£35.50 million
Beta1.8N/AN/AN/AN/A
Average Volume62,844461,037142,4659,567178,769
Sales & Book Value
Annual Revenue$3.50 million£687,584.00£12.09 millionN/A£9.53 million
Price / Sales13.0167.153.61N/A3.70
CashflowN/AGBX 1.82 per shareGBX 15.48 per shareN/AGBX 18.29 per share
Price / CashN/A28.823.37N/A4.02
Book Value$4.29 per shareGBX 6.30 per shareGBX 16.50 per shareN/AGBX 19.40 per share
Price / Book0.720.080.03N/A0.04
Profitability
Net Income$-33,870,000.00N/AN/AN/AN/A
EPS($16.23)GBX (2.30)GBX (20)N/AGBX 2
Trailing P/E RatioN/AN/AN/A0.0036.79
Forward P/E Ratio∞∞∞∞∞
P/E GrowthN/AN/AN/AN/AN/A
Net MarginsN/AN/AN/AN/AN/A
Return on Equity (ROE)-126.85%N/AN/AN/AN/A
Return on Assets (ROA)-82.61%N/AN/AN/AN/A
Dividend
Annual PayoutN/AN/AN/AN/AN/A
Dividend YieldN/AN/AN/AN/AN/A
Three-Year Dividend GrowthN/AN/AN/AN/AN/A
Payout RatioN/AN/AN/AN/AN/A
Years of Consecutive Dividend GrowthN/AN/AN/AN/AN/A
Debt
Debt-to-Equity Ratio0.37%13.35%25.11%N/A2.34%
Current Ratio6.50%2.34%1.37%N/A3.85%
Quick Ratio5.08%2.17%1.16%N/A3.64%
Ownership Information
Institutional Ownership Percentage77.39%N/AN/AN/AN/A
Insider Ownership Percentage50.90%N/AN/AN/AN/A
Miscellaneous
EmployeesN/A10N/AN/A82
Shares Outstanding14.64 million87.94 million83.66 million12.32 million47.97 million
Next Earnings DateN/A5/24/2021 (Estimated)N/AN/A5/17/2021 (Estimated)
OptionableNot OptionableNot OptionableNot OptionableNot OptionableNot Optionable
SourceHeadline
IXICO links up with Microsoft to enhance AI platformIXICO links up with Microsoft to enhance AI platform
proactiveinvestors.co.uk - April 12 at 12:51 PM
CIP Merchant Capital acquires 3.72% stake in Ixico for £1.2mCIP Merchant Capital acquires 3.72% stake in Ixico for £1.2m
stockmarketwire.com - April 12 at 7:51 AM
More Unpleasant Surprises Could Be In Store For IXICO plcs (LON:IXI) Shares After Tumbling 26%More Unpleasant Surprises Could Be In Store For IXICO plc's (LON:IXI) Shares After Tumbling 26%
finance.yahoo.com - April 1 at 3:55 AM
Neuroimaging trailblazer awarded greatest innovatorNeuroimaging trailblazer awarded greatest innovator
raconteur.net - March 26 at 11:30 PM
IXICO plc (LON:IXI) Insider Mark Warne Acquires 14,250 SharesIXICO plc (LON:IXI) Insider Mark Warne Acquires 14,250 Shares
americanbankingnews.com - March 25 at 7:18 AM
IXICO told Huntingtons disease trial to stopIXICO told Huntington's disease trial to stop
proactiveinvestors.co.uk - March 23 at 12:58 PM
Ixico Shares Fall as Roche Halts Huntingtons Disease TrialIxico Shares Fall as Roche Halts Huntington's Disease Trial
morningstar.com - March 23 at 12:58 PM
IXICO plc - Price Monitoring ExtensionIXICO plc - Price Monitoring Extension
proactiveinvestors.com - March 17 at 6:24 PM
IXICO shares rise on pharmaceutical collaboration with MicrosoftIXICO shares rise on pharmaceutical collaboration with Microsoft
lse.co.uk - March 15 at 9:10 AM
IXICO plc - Collaboration with MicrosoftIXICO plc - Collaboration with Microsoft
proactiveinvestors.co.uk - March 15 at 9:10 AM
IXICO to use Microsofts cloud-based AI infrastructure to scale-upIXICO to use Microsoft's cloud-based AI infrastructure to scale-up
proactiveinvestors.co.uk - March 15 at 9:10 AM
Ixico strikes collaboration deal with MicrosoftIxico strikes collaboration deal with Microsoft
sharecast.com - March 15 at 9:10 AM
IXICO plc : IXICO chosen for new Phase II AD studyIXICO plc : IXICO chosen for new Phase II AD study
markets.businessinsider.com - March 11 at 7:34 AM
IXICO chosen to provide services for second Alzheimer’s clinical trial in the span of one weekIXICO chosen to provide services for second Alzheimer’s clinical trial in the span of one week
proactiveinvestors.co.uk - March 11 at 7:34 AM
IXICO plc - IXICO chosen for new Phase II AD studyIXICO plc - IXICO chosen for new Phase II AD study
proactiveinvestors.co.uk - March 10 at 8:49 PM
Ixico selected for Alzheimers clinical trialIxico selected for Alzheimer's clinical trial
sharecast.com - March 10 at 2:00 PM
Ixico tapped to support current clients phase 2 Alzheimers disease clinical trialIxico tapped to support current client's phase 2 Alzheimer's disease clinical trial
stockmarketwire.com - March 10 at 8:59 AM
IXICO announces second Alzheimer’s clinical trial contract in the space of a weekIXICO announces second Alzheimer’s clinical trial contract in the space of a week
proactiveinvestors.co.uk - March 10 at 8:59 AM
IXICO plc - IXICO selected by Cyclerion for a new AD studyIXICO plc - IXICO selected by Cyclerion for a new AD study
proactiveinvestors.co.uk - March 2 at 8:31 AM
IXICO brought in by new client to support Alzheimers trialIXICO brought in by new client to support Alzheimer's trial
proactiveinvestors.co.uk - March 2 at 8:31 AM
IXICO plc - Exercise of Options; PDMR DealingIXICO plc - Exercise of Options; PDMR Dealing
proactiveinvestors.com - March 2 at 12:32 AM
IXICO plc - Conference attendance and presentationsIXICO plc - Conference attendance and presentations
proactiveinvestors.co.uk - March 1 at 9:30 AM
What Can We Learn About IXICOs (LON:IXI) CEO Compensation?What Can We Learn About IXICO's (LON:IXI) CEO Compensation?
finance.yahoo.com - March 1 at 9:30 AM
Digital Biomarker Market Analysis: Global Industry Trends, Share, Key Players, Size, Forecast to 2025Digital Biomarker Market Analysis: Global Industry Trends, Share, Key Players, Size, Forecast to 2025
marketwatch.com - February 25 at 2:01 PM
Europe Clinical Trial Imaging Market Has Huge Growth In Industry 2021 - BioTelemetry, IXICO, Resonance Health, BioclinicaEurope Clinical Trial Imaging Market Has Huge Growth In Industry 2021 - BioTelemetry, IXICO, Resonance Health, Bioclinica
openpr.com - February 12 at 8:10 PM
DateCompanyBrokerageAction
8/13/2018ArsanisPiper Jaffray CompaniesLower Price Target
7/9/2018ArsanisCitigroupDowngrade
7/2/2018ArsanisCowenDowngrade
6/28/2018ArsanisCantor FitzgeraldReiterated Rating
1/7/2019OptiBiotix HealthFinnCapReiterated Rating
10/8/2018HvivoNumis SecuritiesReiterated Rating
9/19/2018HvivoBarclaysUpgrade
3/10/2021IXICOShore CapitalReiterated Rating
(Data available from 4/13/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)
Comparison Ideas:

As Featured By:

MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.